On Tuesday, Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) opened higher 15.73% from the last session, before settling in for the closing price of $14.3. Price fluctuations for AMLX have ranged from $2.60 to $16.96 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -78.71%. Company’s average yearly earnings per share was noted 65.04% at the time writing. With a float of $91.71 million, this company’s outstanding shares have now reached $109.77 million.
Amylyx Pharmaceuticals Inc (AMLX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Amylyx Pharmaceuticals Inc is 16.49%, while institutional ownership is 94.80%. The most recent insider transaction that took place on Jan 15 ’26, was worth 1,850,795. In this transaction Co-Chief Executive Officer of this company sold 136,193 shares at a rate of $13.59, taking the stock ownership to the 3,378,621 shares. Before that another transaction happened on Jan 16 ’26, when Company’s Co-Chief Executive Officer sold 1,974 for $13.83, making the entire transaction worth $27,299. This insider now owns 3,379,465 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.55 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.59) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.77% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Check out the current performance indicators for Amylyx Pharmaceuticals Inc (AMLX). In the past quarter, the stock posted a quick ratio of 13.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.15 in one year’s time.
